Compare STUB & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STUB | PRGO |
|---|---|---|
| Founded | 2000 | 1887 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2025 | 2013 |
| Metric | STUB | PRGO |
|---|---|---|
| Price | $5.87 | $16.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 5 |
| Target Price | $10.54 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 4.5M | 2.7M |
| Earning Date | 11-10-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 7.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $1,745,188,000.00 | $800,000.00 |
| Revenue This Year | $15.84 | N/A |
| Revenue Next Year | $9.82 | $0.74 |
| P/E Ratio | $101.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.22 | $9.23 |
| 52 Week High | $20.54 | $22.01 |
| Indicator | STUB | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 47.68 | 60.32 |
| Support Level | $5.65 | $13.55 |
| Resistance Level | $6.38 | N/A |
| Average True Range (ATR) | 0.27 | 0.66 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 40.51 | 75.87 |
Stubhub Holdings Inc operates a ticketing marketplace for live events where fans can buy tickets from sellers of all types through its StubHub and viagogo websites and mobile applications. The company generates majority of its revenue from United States.
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.